In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Expanding Lilly’s U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

A major pharmaceutical company is making an announcement on Tuesday regarding growth of biopharma innovation in the Rocket ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.